|
|
|
|
|
Highlights from the 2021 American Society of Clinical Oncology Annual Meeting
|
|
|
|
|
|
|
2021 Science of Oncology Award and Lecture
|
|
Arul Chinnaiyan, MD, Ph.D.
|
| Arul Chinnaiyan, MD, PhD Professor of Urology at the University of Michigan was honored with the Science of Oncology Award for facilitating the delivery of precision medicine and advancing the field of cancer genomics and functional biology. Dr. Chinnaiyan delivered the Science of Oncology Award and Lecture during the 2021 ASCO Annual Meeting highlighting work leading to a broader understanding of the incidence of gene fusions in solid tumors. |
|
|
|
|
|
|
|
|
|
| Application of Genomic Testing Treatment for Patients with Prostate Cancer |
| The Application of the Niche: Genomic Medicine in Prostate Trials and Treatments |
| Veda Giri, MD |
| Veda Giri presented genomic medicine in prostate trials and treatments at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. Dr. Giri noted that clinical trials across the entire spectrum of prostate cancer (early stage/low-risk disease, locally advanced/high-risk disease, hormone-sensitive and castration-resistant non-metastatic disease, and hormone-sensitive and castration-resistant metastatic disease) are ongoing, all aiming to improve precision therapy and management. |
|
|
|
|
|
| Medical Oncology Perspective: The Promise and Limitations of Precision Health in Metastatic Disease |
| Franklin Huang, MD, Ph.D. |
| Franklin Huang gave a presentation on the medical oncology perspective of the promise and limitations of precision health in metastatic disease. Dr. Huang notes that the road to precision health in metastatic prostate cancer includes delivering the right therapy to the right patient at the right time. However, there are several ongoing questions that need to be addressed. |
|
|
|
|
|
| Urology Perspective: Application of Precision Health to High-Risk, Localized Disease |
| Edward Schaeffer, MD, Ph.D. |
| During the session discussing the application of genomic testing treatments for patients with prostate cancer, Edward Schaeffer presented the urologists perspective of applying precision health to high-risk, localized disease. |
|
|
|
|
|
| Poster Session - Prostate |
| Immunogenic Priming with 177Lu-PSMA-617 Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: A phase 1b study
|
| Rahul Aggarwal, MD
|
| Rahul Aggarwal presented data assessing whether a single dose of Lu can induce an immunogenic priming effect to improve outcomes of men with mCRPC subsequently treated with the immune checkpoint inhibitor pembrolizumab. A single priming dose 177Lu-PSMA-617 followed by pembrolizumab was well tolerated and leads to durable responses in a subset of mCRPC without high mutational burden or microsatellite instability.
|
|
|
|
|
|
|
|
|
|
|
| PSMA-Targeted Imaging with 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: A Phase 3 Study (CONDOR)—A Subanalysis of Correct Localization Rate and Positive Predictive Value by Standard of Truth |
| Frederic Pouliot, MD, Ph.D., FRCSC |
| Frederic Pouliot presented a subanalysis of correct localization rate and positive predictive value of PSMA-targeted 18F-DCFPyLPET/ CT for each of the pre-defined standard of truth criteria for the CONDOR prospective phase 3 study. |
|
|
|
|
|
| Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-Line Hormonal Treatment (SPLASH)
|
| Kim Chi, MD
|
| Kim Chi presented the design of the SPLASH trial which seeks to prospectively evaluate the efficacy of 177Lu-PNT2002 for men with progressive mCRPC after androgen receptor axis-targeted (ARAT) therapy. The SPLASH trial is currently enrolling patients in Canada and the United States.
|
|
|
|
|
|
| PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial Findings from a Single Center
|
| Michael Uy, MD
|
| Michael Uy presented results of a multi-center registry assessing the ability of PSMA targeted PET/CT to detect sites of disease recurrence and affect patient management. Based on the data, the use of PSMA-PET/CT detected evidence of disease that was not apparent on conventional imaging, resulting in management changes in the majority of patients.
|
|
|
|
|
|
| Health-Related Quality of Life and Patient-Reported Outcomes at Final Analysis of the TITAN Study in Patients with Metastatic Castration-Sensitive Prostate Cancer |
| Neeraj Agarwal, MD |
| Neeraj Agarwal presented HRQoL data from the final analysis of the TITAN study, after cross-over. This final analysis demonstrates that, in addition to improved overall and radiographic progression free survival with the addition of apalutamide to ADT in mCSPC, there is not appreciable difference in patient-reported HRQoL or side effect burden. |
|
|
|
|
|
| The Efficacy of Enzalutamide (ENZA) Plus ADT on Bone Oligometastatic Hormone-Sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES |
| Andrew Armstrong, MD |
| Andrew Armstrong presented a post-hoc analysis of the ARCHES trial aimed at evaluating the efficacy of enzalutamide with ADT in men with bone oligometastatic metastatic hormone-sensitive prostate cancer (mHSPC) compared to polymetastatic mHSPC. |
|
|
|
|
|
| Validation of the Decipher Genomic Classifier in SAKK 09/10: A phase III Randomized Trial Of Dose-Escalated Salvage Radiotherapy After Radical Prostatectomy |
| Alan Dal Pra, MD |
| Alan Dal Pra presented an analysis validating the Decipher genomic classifier within the SAKK 09/10 trial. This study reports a pre-planned secondary analysis of the SAKK 09/10 trial which randomized 350 patients with biochemical recurrence after radical prostatectomy to salvage radiotherapy with 64Gy vs 70Gy. Androgen deprivation therapy (ADT) and pelvic nodal radiotherapy were not utilized within this study. |
|
|
|
|
|
| Real-World Utilization of Advanced Therapies and Racial Disparity Among Patients with Metastatic Castration-Sensitive Prostate Cancer: A Medicare Database Analysis |
| Stephen Freedland, MD |
| Stephen Freedland presented results of an analysis of Medicare data regarding real-world utilization of these agents in men with mCSPC. Based on this large and nationally representative sample of men with mCSPC patients, treatment intensification was uncommonly used with some, but not dramatic, an improvement over time. Importantly, they further showed that treatment intensification was less commonly used in Black and Hispanic patients. |
|
|
|
|
|
| Radiation and Androgen Deprivation Therapy with or Without Docetaxel in the Management of Non-Metastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial |
| Anthony D'Amico, MD, Ph.D. |
| Anthony D’Amico presented results of a randomized controlled trial examining the role of docetaxel with radiation therapy and androgen deprivation therapy in men with non-metastatic unfavorable-risk prostate cancer. The addition of docetaxel to ADT and radiotherapy in men with unfavourable risk prostate cancer did not improve overall survival, though there may be a beneficial effect among men with PSA <4 ng/mL due to decreased prostate cancer related mortality, though this is a post-randomization, hypothesis-generating observation. |
|
|
|
|
|
| First-in-Human Study of TAS3681, an Oral Androgen Receptor Antagonist with AR and AR Splice Variant Downregulation Activity, in Patients with mCRPC Refractory to Abiraterone And/or Enzalutamide and Chemotherapy
|
| Johann de Bono, MD, MSc, Ph.D., FRCP, FMedSci
|
| Johann de Bono presented the dose-escalation part of the first-in-human trial of TAS3681 in patients with mCRPC. TAS3681 is an oral androgen receptor full-length and androgen receptor-splice variant antagonist, which has a manageable safety profile and has antitumor activity against heavily pretreated, multi-drug resistant mCRPC at the recommended phase 2 dose of 300 mg BID.
|
|
|
|
|
|
|
|
| To view our full coverage of the 2021 ASCO Annual Meeting, visit the Conference Coverage section on UroToday.com
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
